ZIM
KRYS icon

Zacks Investment Management’s Krystal Biotech KRYS Stock Holding History

Zacks Investment Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.63M Buy
+17,919
New +$4.77M 0.04% 236
2025
Q1 		– Sell
-9,078
Closed -$1.42M – 711
2024
Q4 		$1.42M Sell
9,078
-369
-4% -$65.5K 0.01% 375
2024
Q3 		$1.72M Buy
9,447
+504
+6% +$97.2K 0.01% 359
2024
Q2 		$1.64M Buy
8,943
+914
+11% +$153K 0.02% 315
2024
Q1 		$1.43M Buy
+8,029
New +$1.12M 0.02% 361

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Zacks Investment Management's KRYS Position: Q1 2026 in Review

Zacks Investment Management opened a new position in Krystal Biotech (KRYS) in Q1 2026: 17,919 shares worth $4.63M. The stake represents 0.04% of the portfolio and ranks #236 among its holdings. This is a return to the name: Zacks Investment Management previously reported a position in KRYS as recently as Q4 2024.

Zacks Investment Management first reported a position in KRYS in Q1 2024 and has held it in 5 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Zacks Investment Management held 17,919 shares of Krystal Biotech worth $4.63M as of Q1 2026.
  • Krystal Biotech was a new Zacks Investment Management position in Q1 2026.
  • Krystal Biotech made up 0.04% of Zacks Investment Management's portfolio in Q1 2026, its #236 holding.
  • Zacks Investment Management first reported a position in Krystal Biotech in Q1 2024 and has held it in 5 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Zacks Investment Management's 13F filing for Q1 2026, filed 14 May 2026.